Detalle Publicación


Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

Título de la revista: CLINICAL CANCER RESEARCH
ISSN: 1078-0432
Volumen: 24
Número: 12
Páginas: 2716 - 2718
Fecha de publicación: 2018
IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNg. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. (C) 2018 AACR.